IFNG and acute lymphoblastic leukemia: This result was consistent with the fact that in the short-term, there was no significant difference in IFNγ cytokine release levels between FMC63- and h1218-CART19 cells against B-cell lymphoma/leukemia lines, including Raji (Burkitt lymphoma), Pfeiffer (DLBCL), Toledo (DLBCL), and Nalm6 (B-ALL) (Fig. 4C).